Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silodosin in Medical Expulsive Therapy for Ureteral Pelvic Stone
NCT02090439Phase 3
Key facts
- Status
- Terminated
- Start
- Jul 2014
- Primary completion
- Dec 2015
- Countries
- 1
- Sponsor
- CHD Vendée
- Modality
- Small Molecules
- Drugs
- silodosin
- Conditions
- nephrolithiasis
01
Overview
Phase 3 trial of silodosin in nephrolithiasis (2 arms), sponsored by CHD Vendée. Primary endpoint: Time to Expel Kidney Stone at 28 days. Started Jul 2014; status: terminated.
02
Design
2 armsstandard treatment with Silodosin
Standard treatment plus Silodosin
standard treatment
Standard treatment alone
03
Who it enrols
Adults aged 18-60 with a first episode of renal colic and a single pelvic ureteral stone 4 to 10 mm, excluding those with severe complications, renal failure, or prior treatment with alpha/calcium channel blockers.
04
Endpoints
Primary
Time to Expel Kidney Stone
Beyond the preview
Go deeper on NCT02090439.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02090439.